<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035161</url>
  </required_header>
  <id_info>
    <org_study_id>MPS-17IPVSS02</org_study_id>
    <nct_id>NCT04035161</nct_id>
  </id_info>
  <brief_title>Evaluation of the Antimicrobial Effectiveness of CHG/IPA</brief_title>
  <official_title>Evaluation of the Antimicrobial Effectiveness of CHG/IPA in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Becton, Dickinson and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Becton, Dickinson and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single site study is a randomized, controlled, partially-blinded design enrolling a&#xD;
      minimum of 516 healthy volunteers, where each subject will receive two of the planned study&#xD;
      products on the product application sites of the abdomen and/or groin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate the antimicrobial activity of the Investigational Product (IP) by comparing&#xD;
      counts of resident skin microbes, obtained after IP application to intact skin of the abdomen&#xD;
      and groin, to counts obtained prior to application.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Actual">December 24, 2019</completion_date>
  <primary_completion_date type="Actual">December 24, 2019</primary_completion_date>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Healthy adult volunteers that meet inclusion/exclusion criteria will be randomized to receive 2 of the 4 products on bilateral site on the abdomen and/or groin.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Study products cannot be blinded to staff member(s) performing product applications, sample collections.&#xD;
Staff member(s) performing bacterial enumeration will be blinded from the identification of all study product assignments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Antimicrobial log10 Reductions From Baseline for Investigational Product and Reference Standard at 30 Seconds and 6 Hours Post-product Application</measure>
    <time_frame>30 seconds and 6 hours post-product application</time_frame>
    <description>Bacterial log10/cm^2 reductions for abdominal and groin sites post-product application (30 seconds and 6 hours) using the Investigational Product or Reference Standard.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antimicrobial Activity (Efficacy): log10 CFU/cm2 of Resident Microbes on Skin at Baseline and 10 Minutes Post-product Application.</measure>
    <time_frame>Baseline and 10 minutes post-product application</time_frame>
    <description>Evaluation of antimicrobial activity will be based on log10 CFU/cm2 of resident microbes on skin before and after each product application on the abdomen and groin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder Rate at 6 Hours Post-Product Application on the Abdomen.</measure>
    <time_frame>6 hours post-product application</time_frame>
    <description>Number of participants with bacterial reduction greater than or equal to baseline (0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder Rate at 6 Hours Post-Product Application on the Groin.</measure>
    <time_frame>6 hours post-product application</time_frame>
    <description>Number of participants with bacterial reduction greater than or equal to baseline (0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antimicrobial Activity (Efficacy): log10 CFU/cm2 of Resident Microbes on Skin at Baseline and 30 Seconds Post-product Application.</measure>
    <time_frame>Baseline and 30 seconds post-product application</time_frame>
    <description>Evaluation of antimicrobial activity will be based on log10 CFU/cm2 of resident microbes on skin before and after each product application on the abdomen and groin.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1935</enrollment>
  <condition>Microbial Colonization</condition>
  <arm_group>
    <arm_group_label>Investigational Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Skin will be prepared with investigational product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Standard</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Skin will be prepared with reference standard</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Skin will be prepared with active comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Skin will be prepared with negative control</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Investigational Product</intervention_name>
    <description>2%(w/v) Chlorhexidine in 70%(v/v) Isopropyl skin preparation</description>
    <arm_group_label>Investigational Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reference Standard</intervention_name>
    <description>60% (v/v) 1-propanol skin preparation</description>
    <arm_group_label>Reference Standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Active Comparator</intervention_name>
    <description>ChloraPrep® SEPP® skin preparation</description>
    <arm_group_label>Active Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Negative Control</intervention_name>
    <description>0.9% Normal Saline skin preparation</description>
    <arm_group_label>Negative Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Read, understand, and provide signed informed consent.&#xD;
&#xD;
          2. Are healthy subjects in good general health&#xD;
&#xD;
          3. Are 18 years of age or older&#xD;
&#xD;
          4. If females of childbearing potential, are using an acceptable form of birth control&#xD;
             for at least 28 days immediately preceding Day 1 and throughout the duration of the&#xD;
             study. Acceptable methods are established, effective hormonal contraception&#xD;
             (oral/implant/injectable/transdermal/intra-vaginal), intra-uterine device [IUD],&#xD;
             diaphragm with spermicide, condom with spermicide, abstinence, bilateral tubal&#xD;
             ligation, or are in a monogamous relationship with a partner who has had a vasectomy&#xD;
&#xD;
          5. In the case of females of childbearing potential, have a negative urine pregnancy test&#xD;
             (UPT) on Product Application Day prior to any applications of the study products.&#xD;
&#xD;
          6. Are free of any systemic or dermatologic disorder, which, in the opinion of the&#xD;
             Investigator, will interfere with the study results or increase the risk of AEs.&#xD;
&#xD;
          7. Have minimal Screening Day bacterial count.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have had exposure to topical or systemic antimicrobials or any other product known to&#xD;
             affect the normal microbial flora of the skin, antibiotics or steroids (other than&#xD;
             hormones for contraception or post-menopausal reasons) within the product restriction&#xD;
             period and for the remainder of the study. Restrictions include, but are not limited&#xD;
             to antimicrobial soaps, antiperspirants/deodorants, shampoos, lotions, perfumes, after&#xD;
             shaves, and colognes.&#xD;
&#xD;
          2. Subjects who have a history of skin allergies.&#xD;
&#xD;
          3. Have known allergies or sensitivity to vinyl, latex (rubber), alcohols, metals, inks,&#xD;
             common consumer/beauty products, tape adhesives, or to common antibacterial agents&#xD;
             found in soaps, lotions, or ointments, particularly chlorhexidine, or any other&#xD;
             product components.&#xD;
&#xD;
          4. Swimming in chemically treated pools or bathing in hot tubs, spas and whirlpools&#xD;
             within the product restriction period and for the remainder of the study.&#xD;
&#xD;
          5. Use of tanning beds, hot waxes, or depilatories, including shaving (in the applicable&#xD;
             product application areas) within the product restriction period and for the remainder&#xD;
             of the study.&#xD;
&#xD;
          6. Have had exposure of the product application sites to strong detergents, acids, bases,&#xD;
             bug repellant, fabric softener-treated clothing, UV treated clothing, other household&#xD;
             chemicals in the applicable product application areas or other irritants during the&#xD;
             product restriction period or during the study period.&#xD;
&#xD;
          7. Have a history of skin cancer within 6 inches of applicable product application areas,&#xD;
             or are currently being treated for skin cancer or have received treatment for any type&#xD;
             of internal cancer within the 5 years prior to enrollment.&#xD;
&#xD;
          8. Subjects who have a history of asthma, diabetes, hepatitis B or C, an organ&#xD;
             transplant, mitral valve prolapse with a heart murmur, congenital heart disease,&#xD;
             lupus, Crohn's disease, medicated multiple sclerosis, internal prosthesis or any&#xD;
             immunocompromised conditions (such as AIDS or HIV positive).&#xD;
&#xD;
          9. A currently active skin disease or inflammatory skin condition (for example contact&#xD;
             dermatitis) anywhere on the body.&#xD;
&#xD;
         10. Any tattoos or scars (including stretch marks) on the product application sites or&#xD;
             within 2 inches of the product application sites; skin blemishes or warts may be&#xD;
             permissible with the specific approval of the Investigator or consulting physician.&#xD;
&#xD;
         11. Dermatoses, cuts, lesions, active skin rashes, scabs, breaks in the skin or other skin&#xD;
             disorders within 6 inches on or around the product application sites.&#xD;
&#xD;
         12. Subjects who have showered or bathed within at least 72 hours of the Product&#xD;
             Application Day. Sponge baths may be taken, however, the lower abdomen and upper thigh&#xD;
             region must be avoided.&#xD;
&#xD;
         13. Subjects who have an irritation score of 1 or greater (any redness, swelling, rash, or&#xD;
             dryness present at any product application area) for any individual skin condition&#xD;
             prior to the Product Application Day baseline sample collection.&#xD;
&#xD;
         14. Are females who are pregnant, plan to become pregnant during the study, or are&#xD;
             breastfeeding a child.&#xD;
&#xD;
         15. Are unable to adhere to or understand the protocol.&#xD;
&#xD;
         16. Have used an investigational drug or participated in an investigational study within&#xD;
             30 days prior to signing the informed consent for this study or are currently&#xD;
             participating in a clinical study.&#xD;
&#xD;
         17. Are employed by or are a family member of staff of BD or the study site conducting the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eurofins Evic Product Testing Romania S.R.L.</name>
      <address>
        <city>Bucharest</city>
        <zip>040256</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <results_first_submitted>June 7, 2021</results_first_submitted>
  <results_first_submitted_qc>July 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2021</results_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT04035161/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT04035161/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were only treated if screening day baseline bacterial counts met the inclusion criteria.&#xD;
Participants were treated with 2 out of 4 study products (Investigational Product, Reference Standard, Active control and Negative Control) 1 on the left side of the body (both groin and abdomen), 1 on the right side of the body (both groin and abdomen).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Study Participants that were treated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated With Investigational Product</title>
              <participants_list>
                <participants group_id="P1" count="609"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated With Reference Standard</title>
              <participants_list>
                <participants group_id="P1" count="419"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated With Active Control</title>
              <participants_list>
                <participants group_id="P1" count="609"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated With Negative Control</title>
              <participants_list>
                <participants group_id="P1" count="605"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All Participants Who Completed Evaluations</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.5" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Antimicrobial log10 Reductions From Baseline for Investigational Product and Reference Standard at 30 Seconds and 6 Hours Post-product Application</title>
        <description>Bacterial log10/cm^2 reductions for abdominal and groin sites post-product application (30 seconds and 6 hours) using the Investigational Product or Reference Standard.</description>
        <time_frame>30 seconds and 6 hours post-product application</time_frame>
        <population>This outcome includes test requirements outlined by Health Canada (HC) for an investigational product to demonstrate immediate and persistent antimicrobial activity against a reference standard, 60% v/v 1-Propanol. This outcome does not include negative and active control comparators. Analysis only includes participants with required treatment day baseline bacterial counts at each anatomical site at baseline and non-missing data at 30 seconds and 6 hours post-product application.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Product</title>
            <description>Single Swabstick impregnated with 1.75mL of 2%(w/v) chlorhexidine gluconate in 70%(v/v) isopropyl alcohol</description>
          </group>
          <group group_id="O2">
            <title>Reference Standard</title>
            <description>1.75 mL of 60% (v/v) 1-propanol applied with a single Swabstick</description>
          </group>
        </group_list>
        <measure>
          <title>Antimicrobial log10 Reductions From Baseline for Investigational Product and Reference Standard at 30 Seconds and 6 Hours Post-product Application</title>
          <description>Bacterial log10/cm^2 reductions for abdominal and groin sites post-product application (30 seconds and 6 hours) using the Investigational Product or Reference Standard.</description>
          <population>This outcome includes test requirements outlined by Health Canada (HC) for an investigational product to demonstrate immediate and persistent antimicrobial activity against a reference standard, 60% v/v 1-Propanol. This outcome does not include negative and active control comparators. Analysis only includes participants with required treatment day baseline bacterial counts at each anatomical site at baseline and non-missing data at 30 seconds and 6 hours post-product application.</population>
          <units>Log10 CFU/cm^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="609"/>
                <count group_id="O2" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdomen 30 Seconds</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" lower_limit="2.39" upper_limit="2.67"/>
                    <measurement group_id="O2" value="2.70" lower_limit="2.53" upper_limit="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdomen 6 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" lower_limit="2.54" upper_limit="2.82"/>
                    <measurement group_id="O2" value="2.73" lower_limit="2.57" upper_limit="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Groin 30 Seconds</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="295"/>
                    <count group_id="O2" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" lower_limit="3.53" upper_limit="3.84"/>
                    <measurement group_id="O2" value="4.07" lower_limit="3.89" upper_limit="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Groin 6 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="295"/>
                    <count group_id="O2" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" lower_limit="3.73" upper_limit="4.04"/>
                    <measurement group_id="O2" value="4.08" lower_limit="3.90" upper_limit="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antimicrobial Activity (Efficacy): log10 CFU/cm2 of Resident Microbes on Skin at Baseline and 10 Minutes Post-product Application.</title>
        <description>Evaluation of antimicrobial activity will be based on log10 CFU/cm2 of resident microbes on skin before and after each product application on the abdomen and groin.</description>
        <time_frame>Baseline and 10 minutes post-product application</time_frame>
        <population>This outcome includes FDA test requirements for an investigational product (IP) to demonstrate superior antimicrobial activity to a negative control and non-inferiority to an active control at the immediate time point of 10 minutes on the abdomen and groin. This outcome does not require a reference standard. Analysis only includes participants with required treatment day baseline bacterial counts at each anatomical site at baseline and non-missing data at 10 minutes post-product application.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Product</title>
            <description>Single Swabstick impregnated with 1.75mL of 2%(w/v) chlorhexidine gluconate in 70%(v/v) isopropyl alcohol</description>
          </group>
          <group group_id="O2">
            <title>Active Control</title>
            <description>ChloraPrep® SEPP® clear applicator- 2% (w/v) chlorhexidine gluconate in 70% (v/v) isopropyl alcohol</description>
          </group>
          <group group_id="O3">
            <title>Negative Control</title>
            <description>1.75mL 0.9% Normal saline applied with a single Swabstick</description>
          </group>
        </group_list>
        <measure>
          <title>Antimicrobial Activity (Efficacy): log10 CFU/cm2 of Resident Microbes on Skin at Baseline and 10 Minutes Post-product Application.</title>
          <description>Evaluation of antimicrobial activity will be based on log10 CFU/cm2 of resident microbes on skin before and after each product application on the abdomen and groin.</description>
          <population>This outcome includes FDA test requirements for an investigational product (IP) to demonstrate superior antimicrobial activity to a negative control and non-inferiority to an active control at the immediate time point of 10 minutes on the abdomen and groin. This outcome does not require a reference standard. Analysis only includes participants with required treatment day baseline bacterial counts at each anatomical site at baseline and non-missing data at 10 minutes post-product application.</population>
          <units>Log10 CFU/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="609"/>
                <count group_id="O2" value="609"/>
                <count group_id="O3" value="605"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdomen Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="307"/>
                    <count group_id="O3" value="303"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread=".61"/>
                    <measurement group_id="O2" value="3.88" spread=".58"/>
                    <measurement group_id="O3" value="4.00" spread=".62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdomen 10 Minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="307"/>
                    <count group_id="O3" value="303"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="1.13"/>
                    <measurement group_id="O2" value="1.31" spread="1.04"/>
                    <measurement group_id="O3" value="3.19" spread=".80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Groin Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="295"/>
                    <count group_id="O2" value="293"/>
                    <count group_id="O3" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.14" spread=".47"/>
                    <measurement group_id="O2" value="6.16" spread=".46"/>
                    <measurement group_id="O3" value="6.17" spread=".48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Groin 10 Minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="295"/>
                    <count group_id="O2" value="293"/>
                    <count group_id="O3" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="1.36"/>
                    <measurement group_id="O2" value="2.70" spread="1.32"/>
                    <measurement group_id="O3" value="4.84" spread=".70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Abdomen at 10 minutes post-product application.&#xD;
Average treatment effect (ATE) of the Investigational Product compared to the Active Control on the abdomen at 10 minutes post-product application. ATE was calculated using a linear regression model for each body site used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority criterion with a 0.5 log10 margin will be implemented for the average treatment effect (ATE) of the Investigational Product compared to the Active Control (i.e., the upper two-sided 95% confidence bound of the post-product application bacterial load corrected for pre-product application bacterial load of the Investigational Product - Active Control should be less than 0.5 log10).</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Groin at 10 minutes post-product application.&#xD;
Average treatment effect (ATE) of the Investigational Product compared to the Active Control on the groin at 10 minutes post-product application. ATE was calculated using a linear regression model for each body site used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority criterion with a 0.5 log10 margin will be implemented for the average treatment effect (ATE) of the Investigational Product compared to the Active Control (i.e., the upper two-sided 95% confidence bound of the post-product application bacterial load corrected for pre-product application bacterial load of the Investigational Product - Active Control should be less than 0.5 log10).</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Abdomen at 10 minutes post-product application.&#xD;
Average treatment effect (ATE) of the Investigational Product compared to the Negative Control on the abdomen at 10 minutes post-product application. ATE was calculated using a linear regression model for each body site used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.66</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Groin at 10 minutes post-product application.&#xD;
Average treatment effect (ATE) of the Investigational Product compared to the Negative Control on the groin at 10 minutes post-product application. ATE was calculated using a linear regression model for each body site used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.19</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Responder Rate at 6 Hours Post-Product Application on the Abdomen.</title>
        <description>Number of participants with bacterial reduction greater than or equal to baseline (0).</description>
        <time_frame>6 hours post-product application</time_frame>
        <population>This outcome includes FDA test requirements to demonstrate persistence of the investigational product (IP) at 6 hours post-product application on the abdomen. This outcome does not require a reference standard. Analysis only includes participants with required treatment day baseline bacterial counts on the abdomen at baseline and non-missing data at 6 hours post-product application.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Product</title>
            <description>Single Swabstick impregnated with 1.75mL of 2%(w/v) chlorhexidine gluconate in 70%(v/v) isopropyl alcohol</description>
          </group>
          <group group_id="O2">
            <title>Active Control</title>
            <description>ChloraPrep® SEPP® clear applicator- 2% (w/v) chlorhexidine gluconate in 70% (v/v) isopropyl alcohol</description>
          </group>
          <group group_id="O3">
            <title>Negative Control</title>
            <description>1.75mL 0.9% Normal saline applied with a single Swabstick</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate at 6 Hours Post-Product Application on the Abdomen.</title>
          <description>Number of participants with bacterial reduction greater than or equal to baseline (0).</description>
          <population>This outcome includes FDA test requirements to demonstrate persistence of the investigational product (IP) at 6 hours post-product application on the abdomen. This outcome does not require a reference standard. Analysis only includes participants with required treatment day baseline bacterial counts on the abdomen at baseline and non-missing data at 6 hours post-product application.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="307"/>
                <count group_id="O3" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286"/>
                    <measurement group_id="O2" value="305"/>
                    <measurement group_id="O3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Responder Rate at 6 Hours Post-Product Application on the Groin.</title>
        <description>Number of participants with bacterial reduction greater than or equal to baseline (0).</description>
        <time_frame>6 hours post-product application</time_frame>
        <population>This outcome includes FDA test requirements to demonstrate persistence of the investigational product (IP) at 6 hours post-product application on the groin. This outcome does not require a reference standard. Analysis only includes participants with required treatment day baseline bacterial counts on the groin at baseline and non-missing data at 6 hours post-product application.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Product</title>
            <description>Single Swabstick impregnated with 1.75mL of 2%(w/v) chlorhexidine gluconate in 70%(v/v) isopropyl alcohol</description>
          </group>
          <group group_id="O2">
            <title>Active Control</title>
            <description>ChloraPrep® SEPP® clear applicator- 2% (w/v) chlorhexidine gluconate in 70% (v/v) isopropyl alcohol</description>
          </group>
          <group group_id="O3">
            <title>Negative Control</title>
            <description>1.75mL 0.9% Normal saline applied with a single Swabstick</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate at 6 Hours Post-Product Application on the Groin.</title>
          <description>Number of participants with bacterial reduction greater than or equal to baseline (0).</description>
          <population>This outcome includes FDA test requirements to demonstrate persistence of the investigational product (IP) at 6 hours post-product application on the groin. This outcome does not require a reference standard. Analysis only includes participants with required treatment day baseline bacterial counts on the groin at baseline and non-missing data at 6 hours post-product application.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295"/>
                    <measurement group_id="O2" value="293"/>
                    <measurement group_id="O3" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antimicrobial Activity (Efficacy): log10 CFU/cm2 of Resident Microbes on Skin at Baseline and 30 Seconds Post-product Application.</title>
        <description>Evaluation of antimicrobial activity will be based on log10 CFU/cm2 of resident microbes on skin before and after each product application on the abdomen and groin.</description>
        <time_frame>Baseline and 30 seconds post-product application</time_frame>
        <population>This outcome includes FDA test requirements for an investigational product (IP) to demonstrate superior antimicrobial activity to a negative control and non-inferiority to an active control at the immediate time point of 30 seconds on the abdomen and groin. This outcome does not require a reference standard. Analysis only includes participants with required treatment day baseline bacterial counts at each anatomical site at baseline and non-missing data at 30 seconds post-product application.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Product</title>
            <description>Single Swabstick impregnated with 1.75mL of 2%(w/v) chlorhexidine gluconate in 70%(v/v) isopropyl alcohol</description>
          </group>
          <group group_id="O2">
            <title>Active Control</title>
            <description>ChloraPrep® SEPP® clear applicator- 2% (w/v) chlorhexidine gluconate in 70% (v/v) isopropyl alcohol</description>
          </group>
          <group group_id="O3">
            <title>Negative Control</title>
            <description>1.75mL 0.9% Normal saline applied with a single Swabstick</description>
          </group>
        </group_list>
        <measure>
          <title>Antimicrobial Activity (Efficacy): log10 CFU/cm2 of Resident Microbes on Skin at Baseline and 30 Seconds Post-product Application.</title>
          <description>Evaluation of antimicrobial activity will be based on log10 CFU/cm2 of resident microbes on skin before and after each product application on the abdomen and groin.</description>
          <population>This outcome includes FDA test requirements for an investigational product (IP) to demonstrate superior antimicrobial activity to a negative control and non-inferiority to an active control at the immediate time point of 30 seconds on the abdomen and groin. This outcome does not require a reference standard. Analysis only includes participants with required treatment day baseline bacterial counts at each anatomical site at baseline and non-missing data at 30 seconds post-product application.</population>
          <units>Log10 CFU/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="609"/>
                <count group_id="O2" value="609"/>
                <count group_id="O3" value="605"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdomen Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="307"/>
                    <count group_id="O3" value="303"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread=".61"/>
                    <measurement group_id="O2" value="3.88" spread=".58"/>
                    <measurement group_id="O3" value="4.00" spread=".62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdomen 30 seconds</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="307"/>
                    <count group_id="O3" value="303"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="1.19"/>
                    <measurement group_id="O2" value="1.30" spread="1.06"/>
                    <measurement group_id="O3" value="3.43" spread=".72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Groin Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="295"/>
                    <count group_id="O2" value="293"/>
                    <count group_id="O3" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.14" spread=".47"/>
                    <measurement group_id="O2" value="6.16" spread=".46"/>
                    <measurement group_id="O3" value="6.17" spread=".48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Groin 30 seconds</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="295"/>
                    <count group_id="O2" value="293"/>
                    <count group_id="O3" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="1.36"/>
                    <measurement group_id="O2" value="2.80" spread="1.34"/>
                    <measurement group_id="O3" value="5.20" spread=".62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Abdomen at 30 seconds post-product application.&#xD;
Average treatment effect (ATE) of the Investigational Product compared to the Active Control on the abdomen at 30 seconds post-product application. ATE was calculated using a linear regression model for each body site used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority criterion with a 0.5 log10 margin will be implemented for the average treatment effect (ATE) of the Investigational Product compared to the Active Control (i.e., the upper two-sided 95% confidence bound of the post-product application bacterial load corrected for pre-product application bacterial load of the Investigational Product - Active Control should be less than 0.5 log10).</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Abdomen at 30 seconds post-product application.&#xD;
Average treatment effect (ATE) of the Investigational Product compared to the Negative Control on the abdomen at 30 seconds post-product application. ATE was calculated using a linear regression model for each body site used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.84</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Investigational Product</title>
          <description>Single Swabstick impregnated with 1.75mL of 2%(w/v) chlorhexidine gluconate in 70%(v/v) isopropyl alcohol</description>
        </group>
        <group group_id="E2">
          <title>Reference Standard</title>
          <description>1.75 mL of 60% (v/v) 1-propanol applied with a single Swabstick</description>
        </group>
        <group group_id="E3">
          <title>Active Control</title>
          <description>ChloraPrep® SEPP® clear applicator- 2% (w/v) chlorhexidine gluconate in 70% (v/v) isopropyl alcohol</description>
        </group>
        <group group_id="E4">
          <title>Negative Control</title>
          <description>1.75mL 0.9% Normal saline applied with a single Swabstick</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="605"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="605"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="605"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Erin Zook, PhD</name_or_title>
      <organization>Becton Dickinson</organization>
      <phone>224-358-5019</phone>
      <email>erin.zook@bd.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

